PCSA
Processa Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
+0.49%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -3.9%
- EBIT
- +0.8%
- EPS
- +90.5%
- Free cash flow
- -5.7%
- Operating cash flow
- -10.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +68.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -14.5%
- EBIT
- -16.1%
- Net income
- -14.5%
- EPS
- +89.3%
- Free cash flow
- -1.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026